Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel
NASDAQ:RADX

Radiopharm Theranostics Q4 2026 Earnings Report

Radiopharm Theranostics logo
$2.41 +0.15 (+6.64%)
As of 08/28/2026 04:00 PM Eastern
ProfileEarnings HistoryForecast

Radiopharm Theranostics EPS Results

Actual EPS
-$0.81
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Radiopharm Theranostics Revenue Results

Actual Revenue
$0.49 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Radiopharm Theranostics Announcement Details

Quarter
Q4 2026
Date
7/31/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Radiopharm Theranostics Earnings Headlines

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
August 26 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/26/3351185/0/en/radiopharm-theranostics-doses-first-patient-in-second-cohort-of-phase-1-2a-clinical-trial-of-betabart-rv-01-in-b7-h3-expressing-solid-tumors.html
Radiopharm Theranostics (NASDAQ:RADX) Stock Price Down 8.4% - Here's Why
August 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30973662
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
August 29 at 1:00 AM  |  Chaikin Analytics (Ad)
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
August 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/20/3348199/0/en/radiopharm-theranostics-receives-positive-recommendation-from-data-safety-and-monitoring-committee-to-advance-to-cohort-4-in-177lu-rad202-phase-1-heat-clinical-trial.html
Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
August 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/radiopharm-theranostics-meet-u-fda-113000466.html
RADX: RAD101 Topline & FY:26 Cash Flows
August 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/radx-rad101-topline-fy-26-151400375.html
See More Radiopharm Theranostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Radiopharm Theranostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Radiopharm Theranostics and other key companies, straight to your email.

About Radiopharm Theranostics

Radiopharm Theranostics (NASDAQ:RADX), Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types. Radiopharm Theranostics collaborates with academic centers and contract development and manufacturing organizations to advance candidates from preclinical studies through clinical trials, with an emphasis on safety, efficacy and scalable production.

Headquartered in Alpharetta, Georgia, Radiopharm Theranostics conducts operations in the United States and is positioning itself for expansion into select international markets. Its management team brings together professionals with deep expertise in radiopharmaceutical chemistry, nuclear medicine and oncology drug development, underscoring the company’s commitment to advancing next-generation diagnostic and therapeutic solutions.

View Radiopharm Theranostics Profile
Earnings Tools